



CLÍNICA E INVESTIGACIÓN EN ARTERIOSCLEROSIS

www.elsevier.es/arterio



CLINICAL REPORT

The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study



Angel Díaz Rodríguez^a, Adalberto Serrano Cumplido^b, Jesús Millán Nuñez-Cortés^c,
Marta Rodríguez de Miguel^d, M^a Luisa Orera-Peña^{d,*}

^a Primary Care Center, Bemibre, León, Spain

^b Primary Care Center, Bizkaia, Spain

^c University Hospital Gregorio Marañón, Madrid, Spain

^d Mylan Medical Department, Spain

Received 9 March 2017; accepted 12 April 2017

Available online 23 June 2017

KEYWORDS

Atherogenic
dyslipidaemia;
Cardiovascular risk;
LDL-C;
HDL-C;
Triglycerides;
Clinical case;
Primary care

Abstract

Background and aims: The “DAT-AP” (from the Spanish, “Dislipemia Aterogénica en Atención Primaria”, for Atherogenic Dyslipidaemia in Primary Care) study objective is to determine to what extent published consensus guidelines for the diagnostic and therapeutic management of AD are used in the primary care setting, and to evaluate the approach of the participating physicians towards the detection, diagnosis, and treatment of AD.

Methods: This is descriptive, cross-sectional, multicentre study performed between January and May 2015 in primary care centres throughout Spain. Study data were collected in 2 independent blocks, the first addressing theoretical aspects of AD and the second, practical aspects (clinical cases)

Results: The theoretical part is in the process of publication. This manuscript depicts the clinical cases block. Although study participants showed good knowledge of the subject, the high prevalence of this disease requires an additional effort to optimise detection and treatment, with the implementation of appropriate lifestyle interventions and the prescription of the best treatment.

© 2017 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: luisa.orera@mylan.com (M.L. Orera-Peña).

PALABRAS CLAVE

Dislipemia
aterogénica;
Riesgo
cardiovascular;
LDL-C;
HDL-C;
Triglicéridos;
Caso clínico;
Atención primaria

Grado de aplicación de los resultados del consenso de dislipemia aterogénica en el ámbito de Atención Primaria. Estudio DAT-AP

Resumen

Introducción y objetivos: El objetivo del estudio "DAT-AP" ("*Dislipemia Aterogénica en Atención Primaria*") es determinar en qué medida las guías de consenso publicadas sobre el manejo diagnóstico y terapéutico de la dislipidemia aterogénica (DA) son utilizadas en el entorno de atención primaria, así como evaluar el abordaje de los médicos participantes en cuanto a la detección, diagnóstico y tratamiento de la DA.

Métodos: Estudio transversal, descriptivo y multicéntrico, realizado entre Enero y Mayo de 2015 en centros de AP de España. Los datos fueron recogidos en 2 bloques independientes, en el que el primero recoge aspectos teóricos de la DA y el segundo aspectos prácticos (casos clínicos).

Resultados: La parte teórica está en proceso de publicación. Este manuscrito describe el bloque relativo a los casos clínicos. Aunque los participantes del estudio mostraron un buen conocimiento de la materia, la alta prevalencia de esta enfermedad requiere un esfuerzo adicional para optimizar la detección y el tratamiento con la implementación de medidas adecuadas sobre el estilo de vida y la prescripción del mejor tratamiento.

© 2017 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

The worldwide obesity epidemic is progressing hand in hand with an increasing incidence of metabolic disorders, such as diabetes, hypercholesterolemia, and atherogenic dyslipidaemia (AD). AD is a typical characteristic in obese patients with metabolic syndrome, insulin resistance and type 2 diabetes,¹ and carries a significant cardiovascular risk.^{2,3} The AD lipid profile is determined by low HDL-cholesterol (HDL-C) levels, elevated triglycerides (TG), and the presence of small, dense LDL particles, a combination that is highly atherogenic. Given its nature, treating AD with statins is frequently insufficient to provide overall lipid profile control, and fails to eliminate the residual vascular risk attributable to the non-LDL components of this lipid abnormality.⁴

Numerous studies have shown that patients with AD benefit from medical treatment targeted at normalising HDL-C and TG,^{5–9} and this evidence has been integrated into recommendations published in clinical practice guidelines.^{10–12} However, while the understanding of the association between an elevated cardiovascular risk and low HDL-C or high TG levels is a complex matter, it is clear that this relationship impacts on both coronary and cerebrovascular disease.^{13,14}

Appropriate diagnosis and therapeutic management of AD in the community would help to reduce the residual risk associated with this disease and affected patients would benefit. In this respect, primary care physicians play a very important role, since they can implement preventive measures in a large percentage of patients, more so than in the hospital setting or the specialised clinic.¹⁵

The main aim of this study was to determine to what extent published consensus guidelines for the diagnostic and therapeutic management of AD¹² are used in the primary care setting, and to evaluate the approach of the

participating physicians towards the detection, diagnosis, and treatment of AD.

Materials and methods**Study design and participants**

The DAT-AP (*Dislipemia Aterogénica en Atención Primaria* – initials of *Atherogenic Dyslipidaemia in Primary Care* in Spanish) study is a descriptive, cross-sectional, multicentre study performed between January and May 2015 in primary care centres throughout Spain. This study was approved by the Clinical Research Ethics Committee of the Hospital Clínico San Carlos, Madrid. Study participants were primary care (PC) physicians involved in the treatment of AD, stratified according to the distribution of the population in Spain.

Study tools

The scientific coordinators of the project developed a computer application to collect the necessary study data in 2 independent blocks, the first addressing theoretical aspects of AD and the second, practical aspects. The theoretical part consisted of 16 questions divided into 5 sections, according to the structure of the consensus document¹²: the nature of AD; impact and epidemiology of AD; cardiovascular risk associated with AD; detection, diagnosis and objectives for control; and treatment. An initial manuscript reporting the results of this first part is currently being prepared for publication. This article reports the results of the practical section, which consisted of 14 questions on 4 predefined clinical cases. The aim was to determine, according to the different items listed, the main features of the diagnostic and therapeutic approach in these proposed cases.

Table 1 Participating family doctors by autonomous community (N=991).

AC	Participants	%
Andalusia	161	16.7
Aragon	32	3.3
Asturias	30	3.1
Balearic Islands	20	2.1
Canary Islands	47	4.9
Cantabria	19	2.0
Castile-Leon	75	7.8
Castile-La Mancha	44	4.6
Catalonia	85	8.8
Extremadura	24	2.5
Galicia	106	11.0
La Rioja	2	0.2
Madrid	94	9.7
Melilla	3	0.3
Murcia	30	3.1
Navarre	11	1.1
Basque Country	51	5.3
Valencia	128	13.3

Each participating investigator was provided with a user name and password to access the online platform to complete the form. In no case was information collected from patients' clinical records or from any specific patient.

Statistical analysis

A descriptive analysis was performed, using mean and standard deviation for quantitative variables and frequencies and percentages for qualitative variables. The statistical analysis was conducted using the statistical package SAS Service pack 3 version 9.1.3.

Results

The study participants comprised 991 PC physicians involved in the management of patients with AD. [Table 1](#) shows the distribution of participating physicians in each autonomous community; representation was highest in Andalusia (16.7%), Valencia (13.3%) and Galicia (11.0%).

Approach to the proposed clinical cases

Case 1. A 52-year-old man admitted to hospital with acute coronary syndrome (ACS). In total, 97% of study participants considered that determination of the lipid profile was essential, since the results of that analysis would guide treatment ([Table 2](#)). Seventy-five percent of respondents considered that in this case it was essential to determine total cholesterol (TC) and LDL-C to assess the patient's cardiovascular risk. Around 90% indicated that if AD was detected, they would treat it at the same time as treating to achieve target LDL-C.

Case 2. A 54-year-old woman with a diagnosis of diabetes mellitus, currently receiving metformin 1700 mg/day.

Overweight, with a waist circumference of 101 cm. Lipid profile: TC 294 mg/dl; triglycerides 294 mg/dl; HDL-C 39 mg/dl; LDL-C: 180; non-HDL-C 196 mg/dl. Eighty-six percent of participants stated that the primary lipid objective in this patient would be to control LDL-C. Nearly 100% stated that once the LDL-C therapeutic target had been achieved, targets would have to be set for control of triglycerides and HDL-C: 66% stated that the most suitable targets for this patient would be triglycerides <150 mg/dl and HDL-C >50 mg/dl. For 95% of the respondents, the drug of choice would be fenofibrate plus a statin, to control LDL-C while simultaneously treating AD ([Table 2](#)).

Case 3. A 56-year-old man, discharged after an acute myocardial infarction. He was prescribed atorvastatin (80 mg/day) and given appropriate recommendations on lifestyle changes. He was readmitted 6 months later for recurrent angina. At that time his lipid profile was: TC 128 mg/dl; triglycerides 254 mg/dl; HDL-C 31 mg/dl; calculated LDL-C 67 mg/dl, so combined treatment was started with atorvastatin 80 mg/day + fenofibrate 145 mg/day. Ninety-nine percent of the physicians stated that they would perform regular lipid monitoring in this patient. According to 91.7% of them, the aim of lipid monitoring would be to control lipid-related residual risk, monitor treatment efficacy and/or monitor the appearance of adverse events. In total, 36% of the participants would monitor every 3 months, and 33% every 6 months ([Table 3](#)).

Case 4. A patient on secondary prevention after ACS 2 years previously. Since then, she has been receiving treatment with atorvastatin 80 mg/day. Currently: BMI: 25, BP: 132/74 mmHg, normal blood glucose, lipid profile with TC: 161 mg/dl, LDL-C: 64 mg/dl, HDL-C: 37 mg/dl, and TG: 295 mg/dl. She is admitted for a new episode of ACS. In total, 97% of participants stated that the factor that may have influenced the appearance of this new event was the patient's residual lipid risk, attributable to AD, and 99% believed that her risk of repeat infarction would have been less if her dyslipidaemia had been treated comprehensively. Ninety-three percent of respondents stated that they would have optimised this patient's treatment to reduce the residual risk, treating her AD after LDL-C control had been achieved. Ninety-five percent answered that they would add 145 mg fenofibrate to her current atorvastatin treatment ([Table 3](#)).

Discussion

In this study, we analysed clinical approaches to 4 proposed clinical cases illustrating different situations, in order to determine the extent to which PC physicians selected from all autonomous communities in Spain understand and apply AD consensus recommendations.¹² The questions were primarily drawn up to investigate the diagnostic and/or therapeutic approach in typical cases commonly seen in routine practice, and to analyse the different diagnostic and therapeutic strategies in each case.

It is widely agreed that the benefit provided by intensive reduction of LDL-C has led to the general acceptance of "LDL-C-centred" measures.¹⁶ However, many patients with target LDL-C levels continue to have a persistent cardiovascular risk or residual risk associated with the presence

Table 2 Response of participants to clinical cases 1 and 2.**Case 1: A 52-year-old man admitted to hospital with acute coronary syndrome**

<i>Do you consider it essential to perform a lipid profile?</i>	<i>n</i>	<i>%</i>
Yes, because it will guide treatment	962	97.1
No, because it will not guide treatment	29	2.9
<i>What components of the lipid profile do you consider necessary for the assessment of this patient's cardiovascular risk?</i>		
Total cholesterol	24	2.4
Total cholesterol, LDL-C	745	75.2
Total cholesterol, LDL-C, triglycerides, HDL-C	149	15.0
Total cholesterol, LDL-C, triglycerides, HDL-C, non-HDL-C	73	7.4
<i>If you detect AD (high triglycerides and low HDL-C), when would you treat it?</i>		
I would not treat, the target is LDL-C	5	0.5
At the same time that I treated to achieve target LDL-C	890	89.8
When I had the LDL-C under control	96	9.7

Case 2: A 54-year-old woman with a diagnosis of diabetes mellitus receiving metformin 1700 mg/day. Overweight, with a waist circumference of 101 cm. Lipid profile: total cholesterol 294 mg/dl; triglycerides 294 mg/dl; HDL-C 39 mg/dl; LDL-C 180; non-HDL-C 196 mg/dl

<i>What would be the primary lipid target in this patient?</i>	<i>n</i>	<i>%</i>
LDL-C	850	85.8
Non-HDL-C	25	2.5
Triglycerides and HDL-C	116	11.7
<i>When the target LDL-C has been achieved, do you think it is necessary to set targets for triglycerides and HDL-C?</i>		
Yes	988	99.7
No	3	0.3
<i>What triglyceride and HDL-C targets are the most suitable for this patient?</i>		
Triglycerides < 150 mg/dl and HDL-C > 50 mg/dl	653	65.9
Triglycerides < 150 mg/dl and HDL-C > 40 mg/dl	227	22.9
Triglycerides < 200 mg/dl and HDL-C > 45 mg/dl	111	11.2
<i>What drug would you use to treat AD in this patient (combined with a statin to control LDL-C in this case)?</i>		
Fenofibrate	946	95.5
Nicotinic acid	3	0.3
Gemfibrozil	42	4.2

of AD, particularly patients with type 2 diabetes, abdominal obesity, and/or metabolic syndrome. Almost all the physicians who participated in this study were aware of the importance of performing a lipid profile for the comprehensive assessment of a patient who has suffered an ACS. The importance of low HDL-C as a source of cardiovascular risk is well established,^{17,18} yet a substantial number of physicians still do not include HDL-C levels when determining lipid profiles, despite the evidence of an inverse prognostic relationship between HDL-C and cardiovascular morbidity and mortality, irrespective of LDL-C concentrations.¹⁹ The role of triglycerides in coronary heart disease is also of key importance. A metaanalysis of 29 prospective studies revealed an odds ratio for coronary risk of 1.72 when individuals with triglycerides in the upper tertile (corresponding to >178 mg/dl) were compared with those with levels in the lower tertile (<115 mg/dl), after adjustment for other principal cardiovascular risk factors.²⁰ Moreover, high non-fasting triglyceride levels can be a marker for cardiovascular risk.²¹

More recently, non-HDL cholesterol figures have gained importance as an indicator of cardiovascular risk, and on

occasions are even thought to have more prognostic value than LDL-C.²² A metaanalysis of studies published between 1994 and 2008 showed that individuals who achieved target LDL-C but did not achieve target non-HDL-C levels had a 32% higher risk than those who achieved both objectives.²³ This may be attributed to the fact that non-HDL-C concentrations reflect not only LDL-C, but also all atherogenic particles in plasma corresponding to lipoproteins that contain apolipoprotein B.²⁴ The European Atherosclerosis Society has set non-HDL-C as a secondary target in the treatment of dyslipidaemia,¹¹ calculated as target LDL-C plus 30 mg/dl. This is a parameter that is easy to calculate (TC minus HDL-C) and does not involve any additional cost.

In high-risk patients, such as those with type 2 diabetes, excess weight, and high cholesterol and triglyceride levels (see study case 2), little concordance emerged on the definition of the therapeutic target after LDL-C has been controlled: only 66% of participants indicated that in women, triglyceride control is achieved at a level of less than 150 mg/dl and HDL-C should be higher than 50 mg/dl, in accordance with international recommendations.^{11,16} This highlights some lack of clarity regarding the treatment

Table 3 Response of participants to clinical cases 3 and 4.

Case 3: A 56-year-old man, discharged after acute myocardial infarction, prescribed atorvastatin (80 mg/day), and lifestyle recommendations. He was readmitted 6 months later for recurrent angina. At that time, his lipid profile was: TC 128 mg/dl; triglycerides 254 mg/dl; HDL-C 31 mg/dl; calculated LDL-C 67 mg/dl, so combined treatment was started with atorvastatin 80 mg/day + fenofibrate 145 mg/day

<i>Would you perform regular blood tests in this patient?</i>	<i>n</i>	<i>%</i>
Yes	985	99.4
No, because it would not change treatment	4	0.4
No, because he should be monitored in a specialised unit	2	0.2
<i>What do you think is the aim of monitoring his lipid profile?</i>		
Controlling lipid-related residual risk	33	3.3
Monitoring treatment efficacy	44	4.5
Monitoring the appearance of adverse events	5	0.5
Any or all of the above	909	91.7
<i>How often would you monitor the patient?</i>		
At the same frequency as for monitoring LDL-C	309	31.20
Every 3 months	357	36.02
Every 6 months	325	32.80

Case 4: A patient on secondary prevention for acute coronary syndrome 2 years previously. Since then, she has been receiving treatment with atorvastatin 80 mg/day. Currently: BMI: 25, BP: 132/74 mmHg, normal blood glucose, lipid profile with TC: 161 mg/dl, LDL-C: 64 mg/dl, HDL-C: 37 mg/dl, and TG: 295 mg/dl. She is admitted for a new episode of ACS

<i>Which factors might have influenced the appearance of this new event?</i>	<i>n</i>	<i>%</i>
The fact that ischaemic heart disease frequently recurs	23	2.3
She had lipid-related residual risk, attributable to AD.	957	96.6
Other emerging risk factors that are poorly defined	11	1.1
<i>Do you think that the risk of repeat infarction could have been reduced if her dyslipidaemia had been comprehensively treated?</i>		
Yes	981	99.0
No	10	1.0
<i>How would you have optimised her treatment to reduce the residual risk?</i>		
Reducing LDL-C even further	60	6.1
Intensifying antihypertensive treatment	11	1.1
When she had achieved LDL-C control, I would have treated her AD	920	92.8
<i>What therapeutic modifications would you now make in her treatment regimen?</i>		
Atorvastatin 80 mg + ezetimib 10 mg	38	3.8
Atorvastatin 80 mg + fenofibrate 145 mg	941	95.0
I would not change her treatment as she already has achieved target LDL-C	12	1.2

of complex cases that, in the absence of a history of cardiovascular disease, must be considered as candidates for primary prevention of atherothrombotic and cardiovascular episodes.²⁵ The situation is different in patients who are already receiving prophylactic treatment (secondary prevention). Despite lipid-lowering treatment, the role of AD as a determinant element among factors contributing to residual cardiovascular risk²⁶ is well known, as confirmed by almost 97% of the participants. Clinicians, then, must (and do, according to the results of this survey) give great importance to regular monitoring of lipid levels, treatment efficacy, and detection of possible adverse effects. However, the frequency of monitoring remains controversial, and, as has been stated, is often influenced more by administrative and financial concerns than by clinical considerations.²⁷

One strategy found to be useful in the overall control of dyslipidaemia is to use combined lipid-lowering treatment,

with the administration of a statin to lower cholesterol in association with a fibrate for AD.^{28–30} Fenofibrate was the option used by most of our participants (over 95%) in combination with statins, compared to the more minority choices of nicotinic acid or gemfibrozil. Indeed, clinical practice guidelines and the European Medicines Agency (EMA) recommend fenofibrate for the treatment of mixed hyperlipidemia together with a statin, when triglycerides and HDL-C are inadequately controlled. The safety of this combination has been demonstrated in several studies,^{31–33} and there is evidence that fenofibrate confers additional clinical benefit on renal function^{34,35} and carbohydrate metabolism.³⁶

Some limitations to the interpretation of our results must be taken into account. As in any qualitative study, our results are exploratory and the conclusions cannot be generalised. As this was a survey, the results represent certain opinions or knowledge, rather than objective data. We do not know if

the participating physicians had received specific training in AD or not, nor did we determine the proportion of patients similar to the proposed cases seen in their daily clinical practice. When an individual case presents, other factors such as adherence, drug interactions, and the psychosocial situation must be taken into account in the comprehensive assessment of the patient, and these aspects were not addressed in this study.

Conclusions

This study is a first attempt to evaluate the approach and knowledge of physicians treating AD in the PC setting, as an initial step towards detecting possible shortcomings in training and the application of expert consensus guidelines in AD. Although study participants showed good knowledge of the subject, the high prevalence of this disease requires an additional effort to optimise detection and treatment, with the implementation of appropriate lifestyle interventions and the prescription of the best treatment. Emphasis must be placed on the need to perform a complete lipid profile for an overall assessment of the patient's cardiovascular risk, and to treat the residual risk associated with high triglycerides and low HDL-C with the recommended combination of a statin and fenofibrate.

Ethical responsibilities

Protection of people and animals. The authors state that no human or animal experiments have been performed for this research.

Confidentiality of data. The authors state that they have followed the protocols of their work centre on the publication of patient data.

Right to privacy and informed consent. The authors state that no patient data appears in this article.

Funding

This study has been financed by Mylan.

Conflict of interests

The authors state that they have no conflict of interests. All authors contributed equally to the preparation of this article.

Acknowledgements

The authors thank Mylan for sponsoring and funding this study, and the SANED group for their technical support during the study and for the statistical analysis of the data.

References

1. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. *Circulation*. 2006;113:20–9.
2. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. *J Am Coll Cardiol*. 2005;45:1003–12.
3. Li C, Ford ES, Tsai J, Zhao G, Balluz LS, Gidding SS. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. *Cardiovasc Diabetol*. 2011;10:46.
4. Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. *Am J Manag Care*. 2009;15:S65–73.
5. Group TBS. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. *Circulation*. 2000;102:21–7.
6. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care*. 2009;32:493–8.
7. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563–74.
8. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). *J Am Coll Cardiol*. 2013;62:1580–4.
9. Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, et al. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. *Cardiovasc Diabetol*. 2016;15:11.
10. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J*. 2011;32:1345–61.
11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012;33:1635–701.
12. Núñez-Cortés JM, Pedro-Botet J, Brea-Hernando Á, Díaz-Rodríguez A, González-Santos P, Hernández-Mijares A, et al. Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica. *Rev Españ Cardiol*. 2014;67:36–44.
13. Reiner Z. Are elevated serum triglycerides really a risk factor for coronary artery disease? *Cardiology*. 2015;131:225–7.
14. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. *JAMA*. 2008;300:2142–52.
15. Cabre JJ, Martin F, Costa B, Piñol JL, Llor JL, Ortega Y, et al. Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care. *BMC Public Health*. 2008;8:251.
1. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased small low-density lipoprotein particle

16. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. Guía de la ESC/EAS sobre el manejo de las dislipemias. *Rev Españ Cardiol*. 2011;64:1168.
17. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. *Am J Cardiol*. 2010;106:757–63.
18. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. *Nutr Metab Cardiovasc Dis*. 2013;23:799–807.
19. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. *Eur J Clin Invest*. 2007;37:925–32.
20. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. *Circulation*. 2007;115:450–8.
21. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet*. 2014;384:626–35.
22. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. *J Am Coll Cardiol*. 2009;53:316–22.
23. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA*. 2012;307:1302–9.
24. Bjornstad P, Eckel RH, Pyle L, Rewers M, Maahs DM, Snell-Bergeon JK, et al. Relation of combined non-high-density lipoprotein cholesterol and apolipoprotein B with atherosclerosis in adults with Type 1 diabetes mellitus. *Am J Cardiol*. 2015;116:1057–62.
25. Ziaieian B, Dinkler J, Guo Y, Watson K. The 2013 ACC/AHA cholesterol treatment guidelines: applicability to patients with diabetes. *Curr Diab Rep*. 2016;16:13.
26. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? *Cardiovasc Diabetol*. 2014;13:26.
27. T.H.E.T.A. Frequency of testing for dyslipidemia: a systematic review and budget impact analysis. *Ont Health Technol Assess Ser*. 2014;14:1–27.
28. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am J Cardiol*. 2005;95:462–8.
29. Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy. *Curr Cardiol Rep*. 2012;14:112–24.
30. Tenenbaum A, Medvedofsky D, Fisman EZ, Buby L, Matetzky S, Tanne D, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. *PLoS ONE*. 2012;7:e35298.
31. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366:1849–61.
32. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. *Am J Cardiol*. 2012;110:1296–301.
33. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. *Diabetes Care*. 2012;35:218–25.
34. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. *Diabetologia*. 2011;54:280–90.
35. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. *Diabetologia*. 2012;55:1641–50.
36. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z, et al. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. *Int J Clin Pharmacol Ther*. 2004;42:212–7.